Spruce Biosciences Awaits Stockholder Vote for Nasdaq Relisting

Spruce Biosciences, Inc., a late-stage biopharmaceutical company specializing in therapies for neurological disorders, has secured conditional approval from The Nasdaq Stock Market to resume trading of its common stock. This approval is contingent upon obtaining stockholder approval for a proposed reverse stock split during the company's 2025 Annual Meeting. Spruce's management believes the reverse split will help meet Nasdaq's minimum bid price requirement, thereby enhancing stockholder value and attracting potential investors. The meeting will be held virtually on July 22, 2025, at which point stockholders are urged to vote on the proposal. The company emphasizes the potential benefits of a higher stock price, which include increased investor interest and eligibility for institutional investments. The trading on Nasdaq is anticipated by August 5, 2025.